Additionally, metformin promotes the cancer-killing capacity of CD8+ T-cells by modulating glycolysis [239,240,241] and downregulates immune checkpoint expression and glycolytic flux through HIF-1α inhibition [242,243]. This evidence concerns the gene HIF1A and cancer.